A collaborative study with Harvard Medical School
Chronic Wound Debridement in an Acute Setting to Facilitate Improved Management Objectives Utilising Bioactive Microfibre Gelling (BMG™) Technology
Publication Details:
Chronic Wound Debridement in an Acute Setting to Facilitate Improved Management Objectives Utilising Bioactive Microfibre Gelling (BMG™) Technology
Wound Details
The study evaluated 10 patient case studies over a 2-week period in an acute setting.
Wound types:- Pressure ulcers (6)
- Surgical wounds (3)
- Biopsy wound (1)
Key Findings and Data:
- Slough reduction from 85% to 36.25% within 2 weeks.
- Granulation tissue increased from 14% to 63.12%.
- Visible reduction in devitalized tissue and improved wound bed condition in 8 out of 10 cases.
- Decrease in infection signs and elimination of odour due to MaxioCel’s antibacterial and anti-biofilm properties.
- Within 14 days: slough reduced to 5% and granulation increased to 95%
Key Insights
- MaxioCel provided rapid and effective debridement within just two weeks.
- MaxioCel’s antibacterial and anti-biofilm properties contributed to infection control.
- Improved wound bed preparation supports faster healing
- Its ease of use and effectiveness in wound debridement make it a valuable addition to clinical practice.
Related Publications
Evaluation of a 100% Chitosan Dressing in the Treatment of Diabetic Foot Ulcers
Chronic Wound Debridement in an Acute Setting
Severe Pressure Ulcer Debridement in the Acute Sector
A Multi-disciplinary Team Approach to the Management
